Related Experiment Video
Updated: Jul 3, 2026

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases
Dean A Wacker1, Keith J Miller
1Bristol-Myers Squibb Research and Development, PO Box 5400, Princeton, NJ 08543, USA. dean.wacker@bms.com
Abstract:
The serotonin 5-HT2C receptor is a G-protein-coupled receptor and is one of the 14 subtypes that constitutes the serotonin receptor family. Agonists of 5-HT2C have been implicated as potential treatments for diseases of significant unmet medical need, including obesity and schizophrenia. Despite approximately 10 years of discovery efforts, 5-HT2C agonists have only recently advanced into the clinic, likely because many of the early drug discovery efforts experienced significant difficulties with attaining receptor selectivity. Several of these issues related to receptor selectivity have now been overcome, resulting in the entry of compounds into advanced clinical trials. This review summarizes the progress in 5-HT2C agonist discovery and clinical development over the last 3 years. [sw1]what are the several issues - several issues relating to receptor selectivity?
Related Concept Videos
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting Neurotransmitter Release or Uptake
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
